Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Other Events
Item 8.01 Other Events.
On January24, 2017, Trovagene,Inc. (the Company) issued a press
release announcing the publication of study results in Clinical
Cancer Research, demonstrating the analytical and clinical
performance of Trovera urine and blood liquid biopsy tests to
quantitatively assess KRAS mutations in patients with
diverse advanced cancers. A copy of the press release is
furnished as Exhibit99.1 to this Form8-K.
Item 9.01. Financial Statements and Exhibits
(d)Exhibits.
|
99.1 |
PressReleaseofTrovagene,Inc.datedJanuary24,2017 |
About Trovagene, Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management. Trovagene, Inc. (NASDAQ:TROV) Recent Trading Information
Trovagene, Inc. (NASDAQ:TROV) closed its last trading session down -0.07 at 2.03 with 292,335 shares trading hands.
